EUVIMEDEUVIMED entdecken
Crossref

Population Pharmacokinetics of Sertraline in Psychiatric and Substance Use Disorders

Cinthya Eloisa Chávez Castillo, Susanna Edith Medellín Garibay, Rosa Del Carmen Milán Segovia iD, Sergio Zarazúa Guzmán, Helgi Jung Cook, Marisol Orocio Contreras, Silvia Romano Moreno

The Journal of Clinical Pharmacology · 2024

DOI: 10.1002/jcph.2457 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2024. Verfasst von Cinthya Eloisa Chávez Castillo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, Faculty of Chemical Sciences, Autonomous University of San Luis Potosi, San Luis Potosí, Mexico. Hauptthemen laut MEDLINE: Sertraline, Cytochrome P-450 CYP2D6, Cytochrome P-450 CYP2C19, Substance-Related Disorders. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Consejo Nacional de Ciencia y Tecnología.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to characterize the population pharmacokinetics of sertraline in Mexican patients with psychiatric and substance use disorders. Fifty‐nine patients (13 to 76 years old) treated with doses of sertraline between 12.5 and 100 mg/day were included. Plasma sertraline concentrations were determined in blood samples and five of the main substances of abuse were determined by rapid tests in urine samples. Demographic, clinical, and pharmacogenetic factors were also evaluated. Population pharmacokinetic analysis was performed using NONMEM software with first‐order conditional estimation method. A one‐compartment model with proportional residual error adequately described the sertraline concentrations versus time. CYP2D6*2 polymorphism and CYP2C19 phenotypes significantly influenced sertraline clearance, which had a population mean value of 66 L/h in the final model. The absorption constant and volume of distribution were fixed at 0.855 1/h and 20.2 L/kg, respectively. The model explained 11.3% of the interindividual variability in sertraline clearance. The presence of the CYP2D6*2 polymorphism caused a 23.1% decrease in sertraline clearance, whereas patients with intermediate and poor phenotype of CYP2C19 showed 19.06% and 48.26% decreases in sertraline clearance, respectively. The model was internally validated by bootstrap and visual predictive check. Finally, stochastic simulations were performed to propose dosing regimens to achieve therapeutic levels that contribute to improving treatment response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SertralineCytochrome P-450 CYP2D6Cytochrome P-450 CYP2C19Substance-Related DisordersHumansMaleMiddle AgedAdultFemaleAgedAdolescentYoung AdultModels, BiologicalMental DisordersPolymorphism, GeneticSelective Serotonin Reuptake InhibitorsMexicoAntidepressive Agents

Stichwörter der Autor:innen

CYP2C19CYP2D6dual disordersdual pathologypopulation pharmacokineticssertraline

Substanzen

SertralineCytochrome P-450 CYP2D6Cytochrome P-450 CYP2C19CYP2C19 protein, humanSelective Serotonin Reuptake InhibitorsAntidepressive Agents

Autor:innen und Institutionen

  • Pharmacy Department, Faculty of Chemical Sciences, Autonomous University of San Luis Potosi, San Luis Potosí, Mexico.
  • Pharmacy Department, Faculty of Chemistry, National Autonomous University of Mexico, Mexico City, Mexico.
  • Neuropsychopharmacology Department, National Institute of Neurology and Neurosurgery, Mexico City, Mexico.
  • Centros de Integración Juvenil A.C., San Luis Potosi, Mexico.

ORCID-Profile: Rosa Del Carmen Milán Segovia

Förderung

  • Consejo Nacional de Ciencia y Tecnología

Zitieren

APA

Castillo, C. E. C., Garibay, S. E. M., Segovia, R. D. C. M., Guzmán, S. Z., Cook, H. J., Contreras, M. O., & Moreno, S. R. (2024). Population Pharmacokinetics of Sertraline in Psychiatric and Substance Use Disorders. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.2457

Vancouver

Castillo CEC, Garibay SEM, Segovia RDCM, Guzmán SZ, Cook HJ, Contreras MO, et al. Population Pharmacokinetics of Sertraline in Psychiatric and Substance Use Disorders. The Journal of Clinical Pharmacology. 2024. doi:10.1002/jcph.2457

BibTeX
@article{Castillo2024,
  author = {Castillo, Cinthya Eloisa Chávez and Garibay, Susanna Edith Medellín and Segovia, Rosa Del Carmen Milán and Guzmán, Sergio Zarazúa and Cook, Helgi Jung and Contreras, Marisol Orocio and Moreno, Silvia Romano},
  title = {Population Pharmacokinetics of Sertraline in Psychiatric and Substance Use Disorders},
  journal = {The Journal of Clinical Pharmacology},
  year = {2024},
  doi = {10.1002/jcph.2457}
}
Kostenlos starten →